SandeepHanda/PixabayPatients at a study at Fenway Health taking a daily single pill of the fixed drug combination bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy) for PEP after sexual exposure had fewer side effects and better completion rates than participants in previous studies of other PEP regimens, Professor Kenneth Mayer and colleagues report in the Journal of Acquired Immune Deficiency Syndromes.
By using the bictegravir-based regimen, which has been effective as HIV treatment, this study addresses some of the existing challenges with previous PEP regimens, including side-effects, completion rates and potential drug-to-drug interactions. These include poorly tolerated regimes with zidovudine, potential drug interactions with boosted protease inhibitors, central nervous system side-effects with efavirenz, liver side-effects with nevirapine, and completion challenges with a current US guideline regimen which requires a twice a day dose of raltegravir.
Read the full story at Aidsmap.
Source : Aidsmap
Related HIV and Co-Infections News
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.